Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience Will Use Sirius Biomarkers to Develop Dx for Severe Sepsis

NEW YORK, March 20 (GenomeWeb News) - Tm Bioscience has exclusively licensed from Sirius Genomics certain patents for biomarkers linked to drugs used to treat severe sepsis.


Tm Bioscience will incorporate these markers into a diagnostic for use by critical-care physicians. The company said it expects to launch the test in the second half of 2007.


Tm said the test "could generate" more than $100 million in the first three years on the market.


Terms of the deal call for Tm Bioscience to provide Sirius an upfront payment of $4 million in two equal installments in the second and third quarters of this year. Sirius will repay this cash from earnings generated on the sale of the test. Tm and Sirius will share the remaining earnings equally over the term of the agreement.


The deal call covers a series of "possible mutations" that can occur in the genes associated with two proteins, protein C and arginine vasopressin.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.